Investors
& Media

Jade Biosciences is focused on developing innovative, best-in-class therapies to address critical unmet needs in autoimmune diseases.

Our lead candidate, JADE101, is designed to inhibit the cytokine APRIL (A Proliferation-Inducing Ligand) and is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a chronic kidney disease that can impair kidney function over time. JADE101 aims to reduce harmful IgA antibodies, lower proteinuria (a key marker of kidney damage), and preserve long-term kidney function. 

Jade’s pipeline also includes, JADE201, an anti-BAFF-R (B-cell activating factor receptor), and JADE301, an anti-IFN-β monoclonal antibody. See our pipeline to learn more.